OXT Therapeutics

OXT Therapeutics is a biotechnology company dedicated to developing novel oxytocin-based therapies for metabolic diseases and obesity. Spun out of the University of California, San Francisco (UCSF), the company focuses on engineering long-acting oxytocin analogs that can effectively regulate appetite and energy expenditure. Its lead development candidate, OXT-101, is designed to treat obesity and Prader-Willi Syndrome by targeting the oxytocin receptor with improved pharmacokinetic properties compared to native oxytocin. The company's research is rooted in the neurobiology of weight regulation and aims to address the significant unmet need in chronic weight management. Backed by venture capital, OXT Therapeutics leverages deep expertise in the oxytocin pathway to create potential first-in-class treatments for patients with severe metabolic disorders.